- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.08. | Biomind Labs Inc: Biomind begins trading on CSE | 2 | Stockwatch | ||
| BIOMIND LABS Aktie jetzt für 0€ handeln | |||||
| 11.08. | Canadian Securities Exchange (CSE): Canadian Securities Exchange Welcomes Listing of Biomind Labs Inc. | 445 | Newsfile | Toronto, Ontario--(Newsfile Corp. - August 11, 2026) - The Canadian Securities Exchange ("CSE" or "the Exchange") today welcomed the listing of Biomind Labs Inc. ("Biomind" or the "Company"). The... ► Artikel lesen | |
| 11.08. | XFRA NEW INSTRUMENTS AVAILABLE ON 11.08.2026 | 322 | Xetra Newsboard | The following instruments on XETRA do have their first trading 11.08.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 11.08.2026
Aktien
1 US0906842002 BioStem Technologies... ► Artikel lesen | |
| 07.08. | CSE Bulletin: New Listing - Biomind Labs Inc. (BMND) | 125 | Newsfile | Le 7 août/August 2026
The common shares of Biomind Labs Inc. have been approved for listing on the CSE.
Listing and disclosure documents will be available at www.thecse.com on the listing date.
Biomind... ► Artikel lesen | |
| 06.08. | Biomind Labs Inc: Biomind Labs to be delisted from Cboe Canada | 1 | Stockwatch | ||
| 06.08. | Biomind Labs Inc.: Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada | 579 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / August 6, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF), a clinical-stage biopharmaceutical company focused on transforming breakthroughs... ► Artikel lesen | |
| 03.07. | Biomind Labs Inc: Biomind Labs delisting review extended | 1 | Stockwatch | ||
| 02.06. | Biomind Labs Inc: Biomind Labs delisting review extended | 1 | Stockwatch | ||
| 21.04. | Biomind Labs Inc: Biomind cheers executive order for psychedelic research | 3 | Stockwatch | ||
| 20.04. | Biomind Labs Inc.: Biomind Labs Applauds Landmark Executive Order Accelerating Psychedelic Research and Access in The United States | 449 | ACCESS Newswire | A defining moment for the future of mental health, and for Biomind's mission to transform neuropsychiatric care through next-generation psychedelic medicines TORONTO, ON / ACCESS Newswire / April 20... ► Artikel lesen | |
| 27.01. | Biomind Labs Inc.: Biomind Labs Announces CAD $2.52 Million Private Placement Financing | 548 | ACCESS Newswire | NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, ON / ACCESS Newswire / January 27, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC... ► Artikel lesen | |
| 27.01. | XFRA DELETION OF INSTRUMENTS FROM XETRA - 27.01.2026 | 256 | Xetra Newsboard | The following instruments on XETRA do have their last trading day on 27.01.2026Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 27.01.2026ISIN NameDE000HEL0GB7 LB.HESS.THR.CARRARA04S/25XS2576250448... ► Artikel lesen | |
| 03.12.25 | Biomind Labs Inc.: Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood | 453 | ACCESS Newswire | BIOMIND LABS ACCELERATES FDA PATHWAY FOR 5-MEO-DMT CANDIDATE BMND08 AND GRANTS STOCK OPTIONS TORONTO, ON / ACCESS Newswire / December 3, 2025 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC... ► Artikel lesen | |
| 01.12.25 | XFRA 3XI: WIEDERAUFNAHME/RESUMPTION | 327 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 25.11.25 | Biomind Labs Inc.: Biomind Labs Announces Revocation of Cease Trade Order | 570 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / November 25, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that the Ontario Securities Commission (the "Commission") has revoked... ► Artikel lesen | |
| 18.11.25 | Biomind Labs Inc.: Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board | 602 | ACCESS Newswire | TORONTO, ON / ACCESS Newswire / November 18, 2025 / Biomind Labs Inc. (the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), announces that it has filed the following continuous disclosure documents... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AAP IMPLANTATE | 1,550 | +4,73 % | aap Implantate: Cornelius Fink und Nicole Kassel neu im Vorstand | Bei aap Implantate kommt es zu Veränderungen im Vorstand. CEO Rubino Di Girolamo wird sein Amt zum 31. Dezember 2026 im Einvernehmen mit dem Aufsichtsrat niederlegen und vorzeitig aus dem Vorstand ausscheiden.... ► Artikel lesen | |
| CLEARMIND MEDICINE | 6,230 | 0,00 % | Clearmind Medicine Inc.: Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder | Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA) Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine... ► Artikel lesen | |
| ALAUNOS THERAPEUTICS | 3,030 | 0,00 % | Paragon Labs Adds Former Apogee Leaders As Alaunos Completes Velaris Acquisition; Stock Up | WASHINGTON (dpa-AFX) - Paragon Labs announced that several former senior executives from Apogee Therapeutics (APGE) have joined its leadership team, while Alaunos Therapeutics, Inc. (TCRT) completed... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,520 | 0,00 % | AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics | ||
| ARCUTIS BIOTHERAPEUTICS | 26,090 | 0,00 % | Arcutis präsentiert Studiendaten zur ZORYVE-Creme bei Säuglingsekzemen | ||
| NURIX THERAPEUTICS | 22,130 | 0,00 % | Nurix Therapeutics Swings To Profit In Q3 On Roche Licensing Revenue | SOUTH SAN FRANCISCO (dpa-AFX) - Nurix Therapeutics, Inc. (NRIX), clinical-stage biopharmaceutical company, reported a swing to profit in the third quarter from a loss in the year-ago period... ► Artikel lesen | |
| DYNE THERAPEUTICS | 15,300 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| IMMUNOVANT | 28,710 | 0,00 % | Immunovant Q1 2027 Earnings Call: Complete Transcript | ||
| KYMERA THERAPEUTICS | 106,68 | 0,00 % | Kymera Therapeutics: Raymond James startet Coverage mit "Outperform"-Rating | ||
| VERA THERAPEUTICS | 26,790 | 0,00 % | Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026 | BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,835 | 0,00 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| EDGEWISE THERAPEUTICS | 36,280 | 0,00 % | Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 | - Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% -
- EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human... ► Artikel lesen | |
| TANGO THERAPEUTICS | 22,230 | 0,00 % | JPMorgan reiterates Tango Therapeutics stock rating ahead of ESMO data | ||
| COGENT BIOSCIENCES | 28,100 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,610 | 0,00 % | Chutes & Ladders-Vir looks to Liu to lead late-stage push |
BIOMIND LABS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -17,78 % bei einem Aktienkurs von 0,148 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMIND LABS INC finden Sie auf Wallstreet Online.